Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (A-TRI-WEEK)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Anna Cruceta, Fundació Clínic per la Recerca Biomèdica
ClinicalTrials.gov Identifier:
NCT01778413
First received: January 18, 2013
Last updated: September 1, 2015
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)